已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

杜瓦卢马布 医学 封锁 胶质母细胞瘤 肿瘤科 内科学 免疫系统 免疫学 免疫疗法 癌症研究 无容量 受体
作者
Lakshmi Nayak,Nathan E. Standifer,Jörg Dietrich,Jennifer Leigh Clarke,Gavin P. Dunn,Michael K. Lim,Timothy Francis Cloughesy,Hui Kong Gan,Elizabeth Flagg,Elizabeth George,Sarah C. Gaffey,Julia Hayden,Christina Holcroft,Patrick Yung Wen,Mary J. Macri,Andrew J. Park,Toni Ricciardi,Aileen Ryan,Paul Otto Schwarzenberger,Ralph Rudolph Venhaus
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:28 (12): 2567-2578 被引量:47
标识
DOI:10.1158/1078-0432.ccr-21-4064
摘要

PURPOSE: PD-L1 is upregulated in glioblastoma and supports immunosuppression. We evaluated PD-L1 blockade with durvalumab among glioblastoma cohorts and investigated potential biomarkers. PATIENTS AND METHODS: MGMT unmethylated newly diagnosed patients received radiotherapy plus durvalumab (cohort A; n = 40). Bevacizumab-naïve, recurrent patients received durvalumab alone (cohort B; n = 31) or in combination with standard bevacizumab (cohort B2; n = 33) or low-dose bevacizumab (cohort B3; n = 33). Bevacizumab-refractory patients received durvalumab plus bevacizumab (cohort C; n = 22). Primary endpoints were: OS-12 (A), PFS-6 (B, B2, B3), and OS-6 (C). Exploratory biomarkers included: a systematic, quantitative, and phenotypic evaluation of circulating immune cells; tumor mutational burden (TMB); and tumor immune activation signature (IAS). RESULTS: No cohort achieved the primary efficacy endpoint. Outcome was comparable among recurrent, bevacizumab-naïve cohorts. No unexpected toxicities were observed. A widespread reduction of effector immune cell subsets was noted among recurrent patients compared with newly diagnosed patients that was partially due to dexamethasone use. A trend of increased CD8+Ki67+ T cells at day 15 was noted among patients who achieved the primary endpoint and were not on dexamethasone. Neither TMB nor IAS predicted outcome. CONCLUSIONS: Patients with recurrent glioblastoma have markedly lower baseline levels of multiple circulating immune cell subsets compared with newly diagnosed patients. An early increase in systemic Ki67+CD8+ cells may warrant further evaluation as a potential biomarker of therapeutic benefit among patients with glioblastoma undergoing checkpoint therapy. Dexamethasone decreased immune cell subsets. PD-L1 blockade and combination with standard or reduced dose bevacizumab was ineffective.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
简单的红酒完成签到 ,获得积分10
1秒前
123发布了新的文献求助10
1秒前
斯文哈密瓜完成签到 ,获得积分10
1秒前
zhubb完成签到 ,获得积分10
1秒前
充电宝的应助被BENRONG采纳,获得10
1秒前
2秒前
2秒前
3秒前
Lucas的应助被hermit采纳,获得10
3秒前
5秒前
5秒前
dingly发布了新的文献求助10
7秒前
英姑的应助被简单的不斜采纳,获得10
7秒前
7秒前
蔥Cong发布了新的文献求助10
8秒前
顺颂时祺完成签到 ,获得积分10
9秒前
碧蓝的羊青完成签到 ,获得积分20
10秒前
别梦寒发布了新的文献求助10
10秒前
田様的应助被丫丫采纳,获得10
10秒前
11秒前
11秒前
关耳发布了新的文献求助10
11秒前
Orange的应助被whz采纳,获得10
13秒前
BENRONG发布了新的文献求助10
13秒前
14秒前
初景发布了新的文献求助10
15秒前
chaoschen完成签到,获得积分10
15秒前
汉堡包的应助被womujk采纳,获得10
16秒前
16秒前
19秒前
20秒前
20秒前
学术小白完成签到,获得积分10
21秒前
风中早晨完成签到 ,获得积分10
22秒前
丫丫发布了新的文献求助10
23秒前
zfj完成签到 ,获得积分10
24秒前
24秒前
25秒前
26秒前
cx发布了新的文献求助150
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179321
求助须知:如何正确求助?哪些是违规求助? 9569818
关于积分的说明 21806854
捐赠科研通 7774780
什么是DOI,文献DOI怎么找? 3433008
关于科研通互助平台的介绍 2556969
邀请新用户注册赠送积分活动 2478701